These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 21634407)

  • 21. Feasibility Study of the Permeability and Uptake of Mesoporous Silica Nanoparticles across the Blood-Brain Barrier.
    Baghirov H; Karaman D; Viitala T; Duchanoy A; Lou YR; Mamaeva V; Pryazhnikov E; Khiroug L; de Lange Davies C; Sahlgren C; Rosenholm JM
    PLoS One; 2016; 11(8):e0160705. PubMed ID: 27547955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Titania coating of mesoporous silica nanoparticles for improved biocompatibility and drug release within blood vessels.
    Farooq A; Shukur A; Astley C; Tosheva L; Kelly P; Whitehead D; Azzawi M
    Acta Biomater; 2018 Aug; 76():208-216. PubMed ID: 29933106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding.
    Wang LS; Wu LC; Lu SY; Chang LL; Teng IT; Yang CM; Ho JA
    ACS Nano; 2010 Aug; 4(8):4371-9. PubMed ID: 20731423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles.
    He X; Nie H; Wang K; Tan W; Wu X; Zhang P
    Anal Chem; 2008 Dec; 80(24):9597-603. PubMed ID: 19007246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme-coated mesoporous silica nanoparticles as efficient antibacterial agents in vivo.
    Li LL; Wang H
    Adv Healthc Mater; 2013 Oct; 2(10):1351-60. PubMed ID: 23526816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorescein isothiocyanate-dyed mesoporous silica nanoparticles for tracking antioxidant delivery.
    Rashidi L; Ganji F; Vasheghani-Farahani E
    IET Nanobiotechnol; 2017 Jun; 11(4):454-462. PubMed ID: 28530196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesoporous silica nanoparticles capped with disulfide-linked PEG gatekeepers for glutathione-mediated controlled release.
    Cui Y; Dong H; Cai X; Wang D; Li Y
    ACS Appl Mater Interfaces; 2012 Jun; 4(6):3177-83. PubMed ID: 22646097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells.
    Huang DM; Chung TH; Hung Y; Lu F; Wu SH; Mou CY; Yao M; Chen YC
    Toxicol Appl Pharmacol; 2008 Sep; 231(2):208-15. PubMed ID: 18519141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape.
    Li L; Liu T; Fu C; Tan L; Meng X; Liu H
    Nanomedicine; 2015 Nov; 11(8):1915-24. PubMed ID: 26238077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and HeLa and normal mouse liver cell biocompatibility and cellular internalization.
    Roggers RA; Lin VS; Trewyn BG
    Mol Pharm; 2012 Sep; 9(9):2770-7. PubMed ID: 22738645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges.
    Rosenholm JM; Sahlgren C; Lindén M
    Nanoscale; 2010 Oct; 2(10):1870-83. PubMed ID: 20730166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
    Li Z; Zhang Y; Feng N
    Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functionalized mesoporous silica nanoparticle-based drug delivery system to rescue acrolein-mediated cell death.
    Cho Y; Shi R; Borgens RB; Ivanisevic A
    Nanomedicine (Lond); 2008 Aug; 3(4):507-19. PubMed ID: 18694313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesoporous silica nanoparticles in medicine--recent advances.
    Mamaeva V; Sahlgren C; Lindén M
    Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular confinement in fluorescent magnetic mesoporous silica nanoparticles: effect of pore size on multifunctionality.
    Zhang J; Rosenholm JM; Gu H
    Chemphyschem; 2012 Jun; 13(8):2016-9. PubMed ID: 22431299
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of shape and pore size of mesoporous silica nanoparticles on serum protein adsorption and RBCs hemolysis.
    Ma Z; Bai J; Wang Y; Jiang X
    ACS Appl Mater Interfaces; 2014 Feb; 6(4):2431-8. PubMed ID: 24460090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers.
    Popat A; Hartono SB; Stahr F; Liu J; Qiao SZ; Qing Max Lu G
    Nanoscale; 2011 Jul; 3(7):2801-18. PubMed ID: 21547299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesoporous silica nanoparticles as nanocarriers.
    Wu SH; Hung Y; Mou CY
    Chem Commun (Camb); 2011 Sep; 47(36):9972-85. PubMed ID: 21716992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage.
    Rosenholm JM; Mamaeva V; Sahlgren C; Lindén M
    Nanomedicine (Lond); 2012 Jan; 7(1):111-20. PubMed ID: 22191780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.